Table A1.
The outcome of pediatric AML. Clinical trials by the Cooperative Study Groups.
| Study Group | Study | Periode | Patients (N) | EFS (%) | OS (%) | Relapse (%) | Source |
|---|---|---|---|---|---|---|---|
| AIEOP | AML2002/01 | 2002–2011 | 482 | 8-years 55.0 ± 2.6 | 8-years 67.7 ± 2.4 | 24 | Pession et al. 2013 [105] |
| AML-BFM | AML-BFM 2012 | 2012–2018 | 324 | 5-years 65 ± 3 | 5-years 82 ± 3 | 22 | Waack et al. 2020 [106] |
| AML-BFM 2004 | 2004–2010 | 521 | 5-years 55 ± 2 | 5-years 74 ± 2 | 29 | Creutzig et al. 2013 [107] | |
| COG | AAML03P1 AAML0531 AAML1031 |
2003–2005 2006–2010 2011–2016 |
340 1022 1097 |
3-years 53 ± 6 3-years 53.1 vs. 46.9 3-years 45.9 ± 3 |
3-years 66 ± 5 3-years 69.4 vs. 65.4 3-years 65.4 ± 3 |
33 ± 6 32.8 vs. 41.3 47.2 |
Cooper et al. 2012 [108] Gamis et al. 2014 [109] Aplenc et al. 2020 [110] |
| JACLS | AML99 | 2000–2002 | 240 | 5-years 61.6 ± 6.5 | 5-years 75.6 ± 5.3 | 32.2 | Tsukimoto et al. 2009 [31] |
| JPLSG | AML05 | 2006–2010 | 443 | 3-years 54.3 ± 2.4 | 3-years 73.2 ± 2.3 | 30.3 | Tomizawa et al. 2013 [32] |
| MRC | MRC AML12 | 1995–2002 | 564 | 10-years 54 | 10-years 63 | 32 | Gibson et al. 2011 [27] |
| MRC AML 17 | 2010–2014 | 5-years 74 | Burnett et al. [111] | ||||
| NOPHO | NOPHO AML 2004 | 2004–2009 | 151 | 3-years 57 ± 5 | 3-years 69 ± 5 | 30 | Abrahamsson et al. 2011 [7] Hasle et al. 2012 [29] |
| 99PPLLSG | PPLLSG AML-98 AML-BFM 2012 |
1998–2002 | 195 | 5-years 46 ± 5 | 5-years 53 ± 5 | 24 | Dluzniewska et al. 2010 [112] Czogala et al. 2021 [113] |
| 27 | |||||||
| 2015–2019 | 131 | 3-years 67 ± 5 | 3 years 75 ± 5 | 17 | |||
| SJCRH | AML02 AML08 |
2002–2008 2008–2017 |
216 285 |
3-years 61 3-years 52.9 |
3-years 71 3-years 74.8 |
21 | Rubnitz et al. 2010 [30] Rubnitz et al. 2019 [114] |
AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica), AML-BFM (Berlin, Frankfurt, Münster), COG (Childhood Oncology Group), JACLS (Japanese Association of Childhood Leukemia Study), JPLSG (Japanese Pediatric Leukemia Study Group), NOPHO (Nordic Society for Pediatric Hematology and Oncology), MRC (Medical Research Council), PPLLSG (Polish Pediatric Leukemia/Lymphoma Study Group), SJCRH (St. Jude Children’s Research Hospital).